Raptor Pharmaceutical Corp. (NASDAQ:RPTP) has been assigned an average recommendation of “Hold” from the eight brokerages that are presently covering the stock. Six investment analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $7.90.

RPTP has been the topic of several analyst reports. Cowen and Company reiterated a “buy” rating and set a $8.00 price target on shares of Raptor Pharmaceutical Corp. in a research report on Friday, August 19th. Zacks Investment Research upgraded shares of Raptor Pharmaceutical Corp. from a “hold” rating to a “buy” rating and set a $7.50 target price on the stock in a research report on Thursday, August 11th. Citigroup Inc. lowered shares of Raptor Pharmaceutical Corp. from a “buy” rating to a “neutral” rating and raised their target price for the company from $6.00 to $8.00 in a research report on Monday, August 8th. Wedbush restated a “neutral” rating and issued a $4.00 target price (down previously from $9.00) on shares of Raptor Pharmaceutical Corp. in a research report on Monday, September 12th. Finally, FBR & Co restated a “hold” rating and issued a $10.00 target price on shares of Raptor Pharmaceutical Corp. in a research report on Tuesday, August 23rd.

Raptor Pharmaceutical Corp. (NASDAQ:RPTP) opened at 8.99 on Thursday. Raptor Pharmaceutical Corp. has a one year low of $2.94 and a one year high of $9.01. The stock has a 50 day moving average of $8.28 and a 200 day moving average of $6.14. The firm’s market cap is $766.90 million.

Raptor Pharmaceutical Corp. (NASDAQ:RPTP) last posted its quarterly earnings results on Thursday, August 4th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.18) by $0.02. The business had revenue of $32.05 million for the quarter, compared to analyst estimates of $28.52 million. Raptor Pharmaceutical Corp. had a negative net margin of 79.29% and a negative return on equity of 66.67%. The firm’s revenue for the quarter was up 37.4% on a year-over-year basis. During the same quarter last year, the business posted ($0.17) EPS. Equities research analysts predict that Raptor Pharmaceutical Corp. will post ($0.90) EPS for the current fiscal year.

Institutional investors have recently added to or reduced their stakes in the stock. ProShare Advisors LLC increased its position in Raptor Pharmaceutical Corp. by 1.4% in the second quarter. ProShare Advisors LLC now owns 73,962 shares of the company’s stock valued at $397,000 after buying an additional 1,012 shares during the last quarter. BlackRock Advisors LLC increased its position in Raptor Pharmaceutical Corp. by 0.6% in the second quarter. BlackRock Advisors LLC now owns 271,894 shares of the company’s stock valued at $1,460,000 after buying an additional 1,698 shares during the last quarter. American International Group Inc. increased its position in Raptor Pharmaceutical Corp. by 4.5% in the second quarter. American International Group Inc. now owns 49,237 shares of the company’s stock valued at $264,000 after buying an additional 2,101 shares during the last quarter. Nationwide Fund Advisors increased its position in Raptor Pharmaceutical Corp. by 9.0% in the second quarter. Nationwide Fund Advisors now owns 55,579 shares of the company’s stock valued at $298,000 after buying an additional 4,569 shares during the last quarter. Finally, Swiss National Bank increased its position in Raptor Pharmaceutical Corp. by 5.7% in the second quarter. Swiss National Bank now owns 132,600 shares of the company’s stock valued at $712,000 after buying an additional 7,200 shares during the last quarter. 54.91% of the stock is owned by hedge funds and other institutional investors.

Raptor Pharmaceutical Corp. Company Profile

Raptor Pharmaceutical Corp. (Raptor) is a biopharmaceutical company. The Company is focused on developing and commercializing transformative treatments for people affected by diseases. Its product, PROCYSBI (cysteamine bitartrate) is a delayed-release capsules for the management of nephropathic cystinosis in adults and children of over six years.

5 Day Chart for NASDAQ:RPTP

Receive News & Stock Ratings for Raptor Pharmaceutical Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Raptor Pharmaceutical Corp. and related stocks with our FREE daily email newsletter.